Rationale and prospects of serum immunoglobulin free light chain (FLC) determination in chronic inflammatory disease;Razionale e prospettive della determinazione delle catene leggere libere del siero nelle patologie infiammatorie croniche

Biochimica Clinica

Volumn 37, Issue 5, 2013, Pages 357-364

  Basile, Umberto ^a   Mussap, Michele ^b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN FREE LIGHT CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; UNCLASSIFIED DRUG;

CHRONIC INFLAMMATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; REVIEW;

EID: 84889246846     PISSN: 03930564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Bence Jones H. Papers on chemical pathology: lecture III. Lancet 1847;2:88-92.
2. Ehrlich P. On immunity with special reference to cell life. Proc Roy Soc Lond 1900;66:424-48.
3. Tiselius A, Kabat EA. An electrophoretic study of immune sera and purified antibody preparations. J Exp Med 1939;69:119-31.
4. Putnam FW, Hardy S. Proteins in multiple myeloma. III. Origin of Bence Jones protein. J Biol Chem 1955;212:361-9.
5. Berggård I, Peterson PA. Polymeric forms of free normal kappa and lambda chains of human immunoglobulin. J Biol Chem 1969;244:4299-307.
6. Edelman GM, Gaily JA. The nature of Bence Jones proteins: chemical similarities to polypeptide chains of myeloma globulins and normal γ-globulins. J Exp Med 1962;116:202-27.
7. Porter RR. Structural studies of immunoglobulins. Science 1973;180:713-6.
8. Solomon A. Bence Jones proteins and light chains of immunoglobulins (first of two parts). N Engl J Med 1976;294:17-23.
9. Sølling J, Sølling K. Free light chains of immunoglobulins in amyloidosis. Acta Med Scand 1979;206:283-7.
10. Mancini G, Carbonara AO, Heremans JF. Immunological quantitation of antigens by single radial immunodiffusion. Immunochemistry 1965;2:235-54.
11. SøIling K. Free light chains of immunoglobulins in normal serum and urine determined by radioimmunoassay. Scand J Clin Lab Invest 1975;35:407-12.
12. Robinson EL, Gowland E, Ward ID, et al. Radioimmunoassay of free light chains of immunoglobulins in urine. Clin Chem 1982;28:2254-8.
13. Brouwer J, Otting-van de Ruit M, Buskung-van der Lely H. Estimation of free light chains of immunoglobulins by enzyme immunoassay. Clin Chim Acta 1985;150:267-74.
14. Tillyer CR, Iqbal J, Raymond J, et al. Immunoturbidimetric assay for estimating free light chains of immunoglobulins in urine and serum. J Clin Pathol 1991;44:466-71.
15. Levinson SS. Studies of Bence Jones proteins by immunonephelometry. Ann Clin Lab Sci 1992;22:100-9.
16. Bernier GM, Putnam FW. Polymerism, polymorphism, and impurities in Bence-Jones proteins. Biochim Biophys Acta 1964;86:295-308.
17. Sølling K. Polymeric forms of free light chains in serum from normal individuals and from patients with renal diseases. Scand J Clin Lab Invest 1976;36:447-52.
18. Levinson SS, Keren DF. Free light chains of immunoglobulins: clinical laboratory analysis. Clin Chem 1994;40:1869-78.
19. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-80
20. Charafeddine KM, Jabbour MN, Kadi RH, et al . Extended use of serum free light chain as a biomarker in lymphoproliferative disorders: a comprehensive review. Am J Clin Pathol 2012;137:890-7.
21. Albertini R, Merlini G. La misura delle catene leggere libere delle immunoglobuline nel siero: aspetti analitici e clinici. Biochim Clin 2010;34:26-9.
22. Dispenzieri A, Kyle RA, Merlini GP, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215-24.
23. Te Velthuis H, Knop I, Tam P, et al. N Latex FLC - new monoclonal high performance assays for the determination of free light chain κ and λ. Clin Chem Lab Med 2011;49:1323-32.
24. Shapiro AL. Synthesis of excess light chains of γ globulin by rabbit lymph node cells. Nature 1966;211:243-5.
25. Boivin D, Provençal M, Gendron S, et al. Purification and characterization of a stimulator of plasmin generation from the antiangiogenic agent Neovastat: identification as immunoglobulin kappa light chain. Arch Biochem Biophys 2004;431:197-206.
26. Sun M, Gao QS, Li L, et al. Proteolytic activity of an antibody light chain. J Immunol 1994;153:5121-6.
27. Thiagarajan P, Dannenbring R, Matsuura K, et al. Monoclonal antibody light chain with prothrombinase activity. Biochemistry 2000;39:6459-65.
28. Jokiranta TS, Solomon A, Pangburn MK, et al. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol 1999;163:4590-6.
29. Redegeld FA, Nijkamp FP. Immunoglobulin free light chains and mast cells: pivotal role in T-cell-mediated immune reactions? Trends Immunol 2003;24:181-5
30. Van den Beucken T, Van Neer N, Sablon E, et al. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains. J Mol Biol 2001;310:591-601.
31. Edmundson AB, Ely KR. Binding of N-formylated chemotactic peptides in crystals of the Mcg light chain dimer: similarities with neutrophil receptors. Mol Immunol 1985;22:463-75.
32. Edmundson AB, Ely KR, Herron JN, et al. The binding of opioid peptides to the Mcg light chain dimer: flexible keys and adjustable locks. Mol Immunol 1987;24:915-35.
33. Redegeld FA, van der Heijden MW, Kool M, et al. Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat Med 2002;8:694-701.
34. Sengul S, Zwizinski C, Simon EE, et al. Endocytosis of light chains induces cytokines through activation of NFkappaB in human proximal tubule cells. Kidney Int 2002;62:1977-88.
35. Teng J, Russell WJ, Gu X, et al. Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest 2004;84:440-51.
36. Meixlsperger S, Köhler F, Wossning T, et al. Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. Immunity 2007;26:323-33.
37. Hutchison CA, Landgren O. Polyclonal immunoglobulin free light chains as a potential biomarker of immune stimulation and inflammation. Clin Chem 2011;57:1387-9
38. Epstein WV, Tan M. Increase of L-chain proteins in the sera of patients with systemic lupus erythematosus and the synovial fluids of patients with peripheral rheumatoid arthritis. Arthritis Rheum 1966;9:713-9.
39. Cooper A, Bluestone R. Free immunoglobulin light chains in connective tissue diseases. Ann Rheum Dis 1968;27:537-43.
40. Sølling K, Sølling J, Rømer FK. Free light chains of immunoglobulins in serum from patients with rheumatoid arthritis, sarcoidosis, chronic infections and pulmonary cancer. Acta Med Scand 1981;209:473-7.
41. Gottenborg JE, Aucouturier F, Goetz J, et al. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjögren syndrome. Ann Rheum Dis 2007;66:23-7.
42. Hopper JE, Golbus J, Meyer C, et al. Urine free light chains in SLE: clonal markers of B-cell activity and potential link to in vivo secreted Ig. J Clin Immunol 2000;20:123-37.
43. Hopper JE, Sequeira W, Martellotto J, et al. Clinical relapse in systemic lupus erythematosus: correlation with antecedent elevation of urinary free light chain immunoglobulin. J Clin Immunol 1989;9:338-50.
44. Aggarwal R, Sequeira W, Kokebie R, et al. Serum free light chains as biomarker for systemic lupus erythematus disease activity. Arthritis Care Res 2011;63:891-8.
45. Smith KGC, Jones RB, Burns SM, et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis. Arthitis Rheum 2006;54:2970-82.
46. Chice L, Cournac JM, Mancini J, et al. Normalization of serum free light chains in patients with systemic lupus erythematosus upon rituximab treatment and correlation with biological disease activity. Clin Rheumatol 2011;30:685-9.
47. Groot Kormelink T, Tekstra J, Thurlings RM, et al. Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity. Ann Rheum Dis 2010;69:2137-44.
48. Redegeld FA, van der Heijden MW, Kool M, et al. Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat Med 2002;8:694-701.
49. Van der Heijden M, Kraneveld A, Redegeld F. Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. Eur J Pharmacol 2006;533:319-26.
50. Thio M, Blokhuis BR, Nijkamp FP, et al. Free immunoglobulin light chains: a novel target in the therapy of inflammatory diseases. Trends Pharmacol Sci 2008;29:170-4.
51. van Houwelingen AH, Kaczynska K, Kraneveld AD, et al. Topical application of F991, an immunoglobulin free light chain antagonist, prevents development of contact sensitivity in mice. Clin Exp Allergy 2007;37:270-5.
52. Kraneveld AD, van der Kleij HP, Kool M, et al. Key role for mast cells in nonatopic asthma. J Immunol 2002;169:2044-53.
53. Kraneveld AD, Kool M, van Houwelingen AH, et al. Elicitation of allergic asthma by immunoglobulin free light chains. Proc Natl Acad Sci USA 2005;102:1578-83.
54. Powe DG, Groot Kormelink T, Sisson M, et al. Evidence for the involvement of free light chain immunoglobulins in allergic and nonallergic rhinitis. J Allergy Clin Immunol 2010;125:139-45.
55. Kayserova J, Capkova S, Skalicka A, et al. Serum immunoglobulin free light chains in severe forms of atopic dermatitis. Scand J Immunol 2010;71:312-6.
56. Groot Kormelink T, Pardo A, Knipping K, et al. Immunoglobulin free light chains are increased in hypersensitivity pneumonitis and idiopathic pulmonary fibrosis. PLoS One 2011;6:e25392.
57. Braber S, Thio M, Blokhuis BR, et al. An association between neutrophils and immunoglobulin free light chains in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:817-24.
58. Schouten B, van Esch BC, van Thuijl AO, et al. Contribution of IgE and immunoglobulin free light chain in the allergic reaction to cow's milk proteins. J Allergy Clin Immunol 2010;125:1308-14.
59. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004;113:832-6.
60. Bibas M, Trotta MP, Cozzi-Lepri A, et al. ICONA Foundation Study Group. Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. Am J Hematol 2012;87:749-53.
61. Engels EA, Pfeiffer RM, Landgren O, et al. Immunologic and virologic predictors of AIDS-related non-Hodgkin lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 2010;54:78-84.
62. Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDSrelated lymphoma. J Clin Oncol 2010;28:773-9.
63. Zignego AL, Giannini C, Ferri C. Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol 2007;13:2467-78.
64. Paroli M, Iannucci G, Accapezzato D. Hepatitis C virus infection and autoimmune diseases. Int J Gen Med 2012;5:903-7.
65. Sansonno D, Russi S, Conteduca V, et al. B-cell frequency in HCV-related mixed cryoglobulinemia. Hepatology 2013;58:448.
66. Monti G, Pioltelli P, Saccardo F, et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virusrelated symptomatic mixed cryoglobulinemias. Arch Intern Med 2005;165:101-5.
67. Terrier B, Sene D, Saadoun D, et al. Serum free light chain assessment in hepatitis C virus-related lymphoproliferative disorders. Ann Rheum Dis 2009;68:89-93.
68. Matsumori A, Shimada M, Jie X, et al. Effects of free immunoglobulin light chains on viral myocarditis. Circ Res 2010;106:1533-40.
69. DeCarli C, Menegus MA, Rudick RA. Free light chains in multiple sclerosis and infections of the CNS. Neurology 1987;37:1334-8.
70. Eickhoff K, Heipertz R, Wikström J. Determination of κ/λ immunoglobulin light chain ratios in CSF from patients with multiple sclerosis and other neurological diseases. Acta Neurol Scand 1978;57:385-95.
71. Rudick RA, French CA, Breton D, et al. Relative diagnostic value of cerebrospinal fluid kappa chains in MS: comparison with other immunoglobulin tests. Neurology 1989;39:964-8.
72. Rudick RA, Peter DR, Bidlack JM, et al. Multiple sclerosis: free light chains in cerebrospinal fluid. Neurology 1985;35:1443-9.
73. Krakauer M, Schaldemose Nielsen H, Jensen J et al. Intrathecal synthesis of free immunoglobulin light chains in multiple sclerosis. Acta Neurol Scand 1998;98:161-5.
74. Fischer C, Arneth B, Koehler J, et al. Kappa free light chains in cerebrospinal fluid as markers of intrathecal immunoglobulin synthesis. Clin Chem 2004;50:1809-13.
75. Presslauer S, Milosavljevic D, Brücke T, et al. Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. J Neurol 2008;255:1508-14.
76. Villar LM, Espiño M, Costa-Frossard L, et al. High levels of cerebrospinal fluid free kappa chains predict conversion to multiple sclerosis. Clin Chim Acta 2012;413:1813-6.
77. Kaplan B, Golderman S, Yahalom G, et al. Free light chains monomer-dimer patterns in the diagnosis of multiple sclerosis. J Immunol Methods 2013;390:74-80.
78. Contini C, Fainardi E, Cultrera R, et al. Evidence of cerebrospinal fluid free kappa light chains in AIDS patients with Toxoplasma gondii encephalitis. J Neuroimmunol 2000;108:221-6.